Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan

Barrios, Vivencio; Escobar, Carlos

doi:10.1517/14656566.2010.484020

Search citation statements

Order By: Relevance

Paper Sections

Select...

Aliskiren Versus Placebo1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2011

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 The dose used in the current study, 40 mg per day, was higher than that used in many other studies. Is there anything different about olmesartan?…”

mentioning

confidence: 72%

Preemptive Olmesartan for the Delay or Prevention of Microalbuminuria in Diabetes

Ingelfinger¹

2011

N Engl J Med

View full text Add to dashboard Cite

“…7 The dose used in the current study, 40 mg per day, was higher than that used in many other studies. Is there anything different about olmesartan?…”

mentioning

confidence: 72%

Preemptive Olmesartan for the Delay or Prevention of Microalbuminuria in Diabetes

Ingelfinger¹

2011

N Engl J Med

View full text Add to dashboard Cite

“…This is important, since the early achievement of BP control has been associated with better outcomes. [61] These and other studies [47,48] have shown that there are no significant differences in the magnitude of BP reduction with aliskiren according to sex or age, or the presence of metabolic syndrome or obesity.…”

Section: Aliskiren Versus Placebomentioning

confidence: 84%

Aliskiren in the Management of Hypertension

Barrios

Escobar

2010

American Journal Cardiovascular Drugs

Self Cite

View full text Add to dashboard Cite

Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) have been shown to be effective drugs in the management of hypertension and to have beneficial effects along the cardiovascular continuum. However, due to compensatory mechanisms, both of these types of agent increase plasma renin activity, which has been reported to have deleterious effects on patient outcomes. Aliskiren is the first nonpeptide orally administered direct renin inhibitor available on the market. Reported data have shown that aliskiren effectively reduces BP alone or in combination with other antihypertensive agents, and has a good tolerability profile. Moreover, this agent reduces plasma renin activity, which in theory could have additional clinical benefits. However, clinical trials analyzing the effects of aliskiren on mortality are still ongoing.

show abstract

Current World Literature

2011

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan

Abstract: In addition to controlling BP, speed of onset of action is an important factor in the management of hypertensive patients and treatments that lower BP rapidly should help to reduce cardiovascular risk.

Cited by 3 publications

References 42 publications

Preemptive Olmesartan for the Delay or Prevention of Microalbuminuria in Diabetes

Preemptive Olmesartan for the Delay or Prevention of Microalbuminuria in Diabetes

Aliskiren in the Management of Hypertension

Current World Literature

Contact Info

Product

Resources

About